Jiangsu Nhwa Pharmaceutical Co., LTD
Symbole: 002262.SZ
SHZ
25.16
CNYPrix du marché aujourd'hui
23.9060
Ratio P/E
2.4589
Ratio PEG
25.35B
Cap MRK
- 0.00%
Rendement DIV
Jiangsu Nhwa Pharmaceutical Co., LTD (002262-SZ) États financiers
Bilan
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 13635.22 | 3493.9 | 2984.2 | 2666 | |||||||||||||||||||
balance-sheet.row.short-term-investments | 5823.3 | 1335 | 1452 | 1058.4 | |||||||||||||||||||
balance-sheet.row.net-receivables | 4452.03 | 1091.7 | 937.3 | 757.7 | |||||||||||||||||||
balance-sheet.row.inventory | 2592.65 | 628.6 | 716.3 | 604.3 | |||||||||||||||||||
balance-sheet.row.other-current-assets | 94.68 | 40.3 | 12.6 | 15.1 | |||||||||||||||||||
balance-sheet.row.total-current-assets | 20774.58 | 5254.6 | 4650.4 | 4043.2 | |||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 5602.51 | 1539.5 | 1303.7 | 1158.3 | |||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.intangible-assets | 1083.69 | 276.2 | 223.8 | 167.5 | |||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 1083.69 | 276.2 | 223.8 | 167.5 | |||||||||||||||||||
balance-sheet.row.long-term-investments | -1914.2 | 157.3 | -1333.4 | -928 | |||||||||||||||||||
balance-sheet.row.tax-assets | 218.31 | 58.3 | 37.5 | 30.7 | |||||||||||||||||||
balance-sheet.row.other-non-current-assets | 3137.07 | 42.3 | 1599.7 | 1225.5 | |||||||||||||||||||
balance-sheet.row.total-non-current-assets | 8127.38 | 2073.6 | 1831.3 | 1654 | |||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.total-assets | 28901.96 | 7328.2 | 6481.7 | 5697.2 | |||||||||||||||||||
balance-sheet.row.account-payables | 1056.28 | 216.3 | 255.7 | 267.2 | |||||||||||||||||||
balance-sheet.row.short-term-debt | 380.84 | 136.8 | 50.6 | 63 | |||||||||||||||||||
balance-sheet.row.tax-payables | 542.85 | 84.1 | 143.6 | 125.7 | |||||||||||||||||||
balance-sheet.row.long-term-debt-total | 57.51 | 0.2 | 42.1 | 47.9 | |||||||||||||||||||
Deferred Revenue Non Current | 223.83 | 53.9 | 58 | 63.6 | |||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 40.67 | - | - | - | |||||||||||||||||||
balance-sheet.row.other-current-liab | 892.5 | 434.5 | 426.8 | 2.2 | |||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 329.6 | 50.2 | 103 | 111.5 | |||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 130.84 | 35.6 | 41.9 | 47.7 | |||||||||||||||||||
balance-sheet.row.total-liab | 3568.94 | 864.2 | 897 | 793.5 | |||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.common-stock | 4030.35 | 1007.6 | 1007.6 | 1007.6 | |||||||||||||||||||
balance-sheet.row.retained-earnings | 18875.34 | 4813 | 3978.4 | 3366.1 | |||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 2478.66 | 611.2 | 617.6 | 528.3 | |||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 21.03 | 2.3 | 18.7 | 18.7 | |||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 25405.37 | 6434.1 | 5622.2 | 4920.7 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 28901.96 | 7328.2 | 6481.7 | 5697.2 | |||||||||||||||||||
balance-sheet.row.minority-interest | -126.22 | -24 | -37.5 | -17 | |||||||||||||||||||
balance-sheet.row.total-equity | 25279.15 | 6410.1 | 5584.8 | 4903.7 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 28901.96 | - | - | - | |||||||||||||||||||
Total Investments | 3909.1 | 1492.3 | 118.6 | 130.4 | |||||||||||||||||||
balance-sheet.row.total-debt | 512.6 | 172.6 | 92.8 | 110.9 | |||||||||||||||||||
balance-sheet.row.net-debt | -7299.32 | -1986.4 | -1439.4 | -1496.7 |
Tableau des flux de trésorerie
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 1074.77 | 1036.9 | 880.4 | 798 | |||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 9.99 | 175.1 | 148.7 | 135.1 | |||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -23.2 | -4 | 0.5 | |||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -528.7 | 4 | 2.5 | |||||||||||||||||||
cash-flows.row.change-in-working-capital | -144.64 | -178.6 | -160.6 | -251.1 | |||||||||||||||||||
cash-flows.row.account-receivables | -199.06 | -199.1 | -155.3 | -122.9 | |||||||||||||||||||
cash-flows.row.inventory | 54.43 | 54.4 | -128.2 | -205.9 | |||||||||||||||||||
cash-flows.row.account-payables | 0 | -33.9 | 126.9 | 77.1 | |||||||||||||||||||
cash-flows.row.other-working-capital | -0.01 | 0 | -4 | 0.5 | |||||||||||||||||||
cash-flows.row.other-non-cash-items | -49.47 | 569 | -7.5 | 16.1 | |||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 890.65 | 0 | 0 | 0 | |||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -348.07 | -374 | -327.8 | -206.1 | |||||||||||||||||||
cash-flows.row.acquisitions-net | 1.16 | 1.4 | 0.1 | 0.2 | |||||||||||||||||||
cash-flows.row.purchases-of-investments | -6453.5 | -6453.5 | -5527.5 | 0.3 | |||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 6518.29 | 6490.5 | 32.4 | 34.5 | |||||||||||||||||||
cash-flows.row.other-investing-activites | -313.73 | 0 | 5133.9 | -221.4 | |||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -595.85 | -335.6 | -688.9 | -392.5 | |||||||||||||||||||
cash-flows.row.debt-repayment | -65 | -25 | -48 | -38 | |||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0.5 | |||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | -0.5 | |||||||||||||||||||
cash-flows.row.dividends-paid | -206.97 | -201.5 | -202.7 | -102.3 | |||||||||||||||||||
cash-flows.row.other-financing-activites | 15.5 | -1.1 | 10 | 12.9 | |||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -215.97 | -210.2 | -240.8 | -127.4 | |||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.53 | 0.4 | 0.9 | -1.1 | |||||||||||||||||||
cash-flows.row.net-change-in-cash | 105.47 | 626.7 | -67.7 | 180 | |||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 7750.42 | 2158.9 | 1504.5 | 1572.2 | |||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 7644.95 | 1532.2 | 1572.2 | 1392.2 | |||||||||||||||||||
cash-flows.row.operating-cash-flow | 890.65 | 1050.5 | 861 | 701.1 | |||||||||||||||||||
cash-flows.row.capital-expenditure | -348.07 | -374 | -327.8 | -206.1 | |||||||||||||||||||
cash-flows.row.free-cash-flow | 542.57 | 676.6 | 533.3 | 495 |
Row du compte de résultat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 5182.87 | 4973.5 | 4298.5 | 3935.7 | |||||||||||||||||||
income-statement-row.row.cost-of-revenue | 1479.99 | 1460.4 | 1020.5 | 897.3 | |||||||||||||||||||
income-statement-row.row.gross-profit | 3702.89 | 3513.1 | 3278.1 | 3038.3 | |||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||
income-statement-row.row.research-development | 571.7 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-general-administrative | 48.23 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1753.34 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-expenses | -22.02 | -25.5 | 159 | 126.2 | |||||||||||||||||||
income-statement-row.row.operating-expenses | 2586.71 | 2443.5 | 2312.2 | 2116 | |||||||||||||||||||
income-statement-row.row.cost-and-expenses | 4066.7 | 3903.9 | 3332.7 | 3013.3 | |||||||||||||||||||
income-statement-row.row.interest-income | 19.62 | 23.8 | 25.5 | 17.7 | |||||||||||||||||||
income-statement-row.row.interest-expense | 4.89 | 4.2 | 4.9 | 5.1 | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1753.34 | - | - | - | |||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 64.73 | 89.4 | -13.6 | -10.1 | |||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-operating-expenses | -22.02 | -25.5 | 159 | 126.2 | |||||||||||||||||||
income-statement-row.row.total-operating-expenses | 64.73 | 89.4 | -13.6 | -10.1 | |||||||||||||||||||
income-statement-row.row.interest-expense | 4.89 | 4.2 | 4.9 | 5.1 | |||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 89.4 | 175.1 | 159.4 | 173.2 | |||||||||||||||||||
income-statement-row.row.ebitda-caps | 1239.16 | - | - | - | |||||||||||||||||||
income-statement-row.row.operating-income | 1136.69 | 1069.6 | 1003.5 | 925.9 | |||||||||||||||||||
income-statement-row.row.income-before-tax | 1201.43 | 1159 | 989.9 | 915.8 | |||||||||||||||||||
income-statement-row.row.income-tax-expense | 136.17 | 134.4 | 109.5 | 117.8 | |||||||||||||||||||
income-statement-row.row.net-income | 1074.77 | 1036.9 | 900.7 | 797.8 |
Questions fréquemment posées
Quel est le total de Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) de l'actif total?
Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) Le total des actifs est 7328195368.000.
Quel est le revenu annuel de l'entreprise?
Le revenu annuel est 2705694560.000.
Quelle est la marge bénéficiaire de l'entreprise?
La marge bénéficiaire de l'entreprise est 0.714.
Quel est le flux de trésorerie disponible de l'entreprise?
Le flux de trésorerie disponible est 0.538.
Quelle est la marge bénéficiaire nette de l'entreprise?
La marge bénéficiaire nette est 0.207.
Quel est le revenu total de l'entreprise?
Le revenu total est 0.219.
Qu'est-ce que Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ) bénéfice net (revenu net)?
Le bénéfice net (revenu net) est 1036918058.000.
Quel est l'endettement total de l'entreprise?
La dette totale est 172558561.000.
Quel est le montant des dépenses d'exploitation?
Les dépenses d'exploitation sont 2443472552.000.
Quel est le montant de la trésorerie de l'entreprise?
Les liquidités de l'entreprise sont 1635420861.000.